#ageing

This episode we explore Positive Impact. UCLB is helping to create a new generation of businesses from UCL academics specifically with positive societal impact at their heart. The commercialisation process can be a long road requiring financial, legal, and practical support. Nigel Campbell meets two inventors, Buffy Price Co-founder and COO of Carbon Re, an AI and Climate Tech company spinout from UCL and Cambridge, and Professor Pete Coffey from UCL Institute of Ophthalmology and Founder of Tenpoint Therapeutics; both who are on that journey on how their inventions might improve our future world. We also talk to Dr Anne Lane, CEO of UCLB to find out how UCLB finds the bright ideas which will improve lives, and what it takes to scale to a point where they are having true impact.

Date of episode recording: 2024-02-06T00:00:00Z
Duration: 00:35:54
Language of episode: English
Presenter: Nigel Campbell
Guests: Anne Lane; Buffy Price; Prof Pete Coffey
Producer: Nora Amin
 
For more information: https://www.uclb.com/podcasts/

With its hypothesis-free, target-free, AI-driven drug discovery platform, Fountain Therapeutics is turning the traditional drug discovery pathway on its ear to address a variety of age-related disease. On this week's episode of the Business of Biotech, Fountain CEO William Greene, M.D. joins us to discuss the approach, its rationale,  and how the company is applying substantial support from the likes of Eli Lilly, Alexandria Venture Investments, R42 Group,  Khosla Ventures, and Nan Fung Life Sciences.

Subscribe to the #BusinessofBiotech newsletter at bioprocessonline.com/bob for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at bioprocessonline.com/bob!